Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa

AIDS

Volumn 25, Issue 12, 2011, Pages 1554-1555

  Lawn, Stephen D ^a   Harries, Anthony D ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; RIFAMPICIN;

ANTIVIRAL THERAPY; CAUSE OF DEATH; DISEASE ASSOCIATION; DRUG PROGRAM; HUMAN; INTERVENTION STUDY; LETTER; OBSERVATIONAL STUDY; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SOUTH AFRICA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HIV-1; RISK FACTORS; SOUTH AFRICA; TUBERCULOSIS; VIRAL LOAD;

EID: 79960483538     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348fb61     Document Type: Letter

References (11)

1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
2. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5:18-26.
3. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; [Epub ahead of print].
4. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Dos Santos Filho E, et al. Potential utility of empirical tuberculosis treatment in HIV-infected patients with advanced immunodeficiency in high HIV-TB burden settings. Int J Tuberc Lung Dis 2011; 15:287-295.
5. Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (Suppl 5): S5-S13.
6. Grant AD, Fielding KL, Charalambous S, Chaisson RE, Churchyard GJ. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?. AIDS 2010; 24 (Suppl 5):S15-S18.
7. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2010: CD000171. doi: 10.1002/14651858. CD000171.pub3.
8. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875-1880.
9. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829.
10. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
11. WHO. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. World Health Organization, Geneva, December 2010. [Accessed 8 Decmber 2010]. http://www.who.int/tb/laboratory/roadmap-xpert-mtb-rif-rev23dec2010.pdf.